BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 23796793)

  • 1. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies.
    Ladabaum U; Allen J; Wandell M; Ramsey S
    Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1567-76. PubMed ID: 23796793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
    Sharaf RN; Ladabaum U
    Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of colorectal cancer screening in Germany: current endoscopic and fecal testing strategies versus plasma methylated Septin 9 DNA.
    Ladabaum U; Alvarez-Osorio L; Rösch T; Brueggenjuergen B
    Endosc Int Open; 2014 Jun; 2(2):E96-E104. PubMed ID: 26135268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood.
    Payne SR
    Epigenomics; 2010 Aug; 2(4):575-85. PubMed ID: 22121975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer.
    Warren JD; Xiong W; Bunker AM; Vaughn CP; Furtado LV; Roberts WL; Fang JC; Samowitz WS; Heichman KA
    BMC Med; 2011 Dec; 9():133. PubMed ID: 22168215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SEPT9: A Specific Circulating Biomarker for Colorectal Cancer.
    Song L; Li Y
    Adv Clin Chem; 2015; 72():171-204. PubMed ID: 26471083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality.
    D'Andrea E; Ahnen DJ; Sussman DA; Najafzadeh M
    Cancer Med; 2020 Jan; 9(2):824-836. PubMed ID: 31777197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of
    Sun J; Fei F; Zhang M; Li Y; Zhang X; Zhu S; Zhang S
    BMC Cancer; 2019 May; 19(1):450. PubMed ID: 31088406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study.
    Ørntoft MB; Nielsen HJ; Ørntoft TF; Andersen CL;
    BMC Cancer; 2015 Oct; 15():819. PubMed ID: 26514170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer.
    deVos T; Tetzner R; Model F; Weiss G; Schuster M; Distler J; Steiger KV; Grützmann R; Pilarsky C; Habermann JK; Fleshner PR; Oubre BM; Day R; Sledziewski AZ; Lofton-Day C
    Clin Chem; 2009 Jul; 55(7):1337-46. PubMed ID: 19406918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
    Ladabaum U; Mannalithara A
    Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals.
    Ladabaum U; Mannalithara A; Jandorf L; Itzkowitz SH
    Cancer; 2015 Apr; 121(7):1088-97. PubMed ID: 25492455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.
    Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM
    Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
    Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
    Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of Colorectal Cancer Using a Simplified SEPT9 Gene Methylation Assay Is a Reliable Method for Opportunistic Screening.
    Wu D; Zhou G; Jin P; Zhu J; Li S; Wu Q; Wang G; Sheng J; Wang J; Song L; Han X; Qian J
    J Mol Diagn; 2016 Jul; 18(4):535-45. PubMed ID: 27133379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests.
    Peterse EFP; Meester RGS; de Jonge L; Omidvari AH; Alarid-Escudero F; Knudsen AB; Zauber AG; Lansdorp-Vogelaar I
    J Natl Cancer Inst; 2021 Feb; 113(2):154-161. PubMed ID: 32761199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
    Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
    Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
    Sonnenberg A; Delcò F; Inadomi JM
    Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.